Abstract
The amniotic fluid (AF) provides a source of stem cells with potential use for in utero cell gene therapy to treat congenital disease for the following reasons: (1) amniotic fluid stem cells (AFSCs) are broadly multipotent with high self-renewal capacity, low antigenicity that are able to differentiate into lineages of all three germ layers but are not tumorigenic when injected in vivo; (2) collection of AF can be performed with patient consent at various stages of pregnancy such as amniocentesis, amnio-drainage, or during caesarean delivery, giving a wide range of gestational ages; (3) a variety of stem cell populations are available, which can differentiate down hematopoietic and mesenchymal lineages. Expansion of mesenchymal derived–AFSCs is straightforward, and biobanks are becoming available. Maintaining hematopoiesis after AFSC expansion is more challenging. In this chapter we will discuss how AFSCs could be used in allogeneic or autologous transplantation to treat congenital disease in utero.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
More From: Perinatal Stem Cells
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
